Keryx, Aeterna Zentaris execute perifosine license termination and technology transfer agreement

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the Company and Aeterna Zentaris Inc. have executed a License Termination and Technology Transfer Agreement, whereby the KRX-0401 (perifosine) license agreement has been terminated and all license rights have reverted back to Aeterna Zentaris. 

In exchange for the transfer of the U.S. Investigational New Drug Application, development data, intellectual property and contracts to Aeterna Zentaris, Aeterna Zentaris has assumed all costs related to the Perifosine program going forward and Keryx shall receive a low single-digit royalty on future net sales of perifosine in the U.S., Canada and Mexico.  Aeterna Zentaris plans to continue the Phase 3 study in relapsed/refractory multiple myeloma.  


Keryx Biopharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.